FDA advisors' scrutiny of MDMA therapy is 'temporary setback,' says Harvard researcher
Podcast |
WBUR News
Publisher |
WBUR
Media Type |
audio
Categories Via RSS |
News
Publication Date |
Jun 06, 2024
Episode Duration |
00:05:06

Some Boston-area researchers said the decision by advisors to the U.S. Food and Drug Administration reflected challenges facing regulators as psychedelic treatments enter mainstream psychiatry.

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review